9 Kick starts the regulatory filing of its first biosimilar Pegfilgrastim with EU regulators and expects to file with USFDA subsequently. More so, it reiterates for regulatory submissionofotherbiosimilars(Trastuzumab,Adalimumab,InsulinGlargine)intheUS aswellasEuropeinFY17.Thesefourhasaddressablemarketof>US$30bn. Keyhighlights:INDASsalessaw21%growthledbystrongperformanceacrossallsegment Biopharma(includesSmallmoleculesandBiologics)up19%yoydrivenbyhealthysalesof biosimilarsinemergingmarkets.Brandedformulationsandresearchserviceswereup41% and 18% yoy, respectively. EBITDA was 14% better than our estimates, as the margins at...